open access

Ahead of print
Review articles
Published online: 2018-10-16
Get Citation

Cardiovascular complications after radiotherapy

Izabela Nabiałek-Trojanowska, Ewa Lewicka, Anna Wrona, Anna M. Kaleta, Zuzanna Lewicka-Potocka, Grzegorz Raczak, Rafał Dziadziuszko
DOI: 10.5603/CJ.a2018.0120
·
Pubmed: 30338841

open access

Ahead of print
Review articles
Published online: 2018-10-16

Abstract

Over the past decades, effective cancer therapies have resulted in a significant improvement in the survival rates for a number of cancers and an increase in the number of cancer survivors. Radiation therapy is widely used in the treatment of cancer, and it can induce various cardiotoxicities that differ considerably from chemotherapy-induced cardiotoxicity. They occur primarily as late radiation-induced complications, several years from the end of anticancer treatment and present as coronary artery disease, heart failure, pericardial disease, valvular heart disease and arrhythmias. Patients who recovered from cancer disease suffer from cardiac complications of anticancer treatment, it affects the quality of their lives and life expectancy, especially if the diagnosis is delayed. These patients may present distinct symptoms of cardiac injury, resulting from radiation-induced neurotoxicity and altered pain perception, which makes diagnosis difficult. This review highlights the need for a screening programme for patients who have undergone radiation therapy and which will subsequently have a potentially profound impact on morbidity and mortality.

Abstract

Over the past decades, effective cancer therapies have resulted in a significant improvement in the survival rates for a number of cancers and an increase in the number of cancer survivors. Radiation therapy is widely used in the treatment of cancer, and it can induce various cardiotoxicities that differ considerably from chemotherapy-induced cardiotoxicity. They occur primarily as late radiation-induced complications, several years from the end of anticancer treatment and present as coronary artery disease, heart failure, pericardial disease, valvular heart disease and arrhythmias. Patients who recovered from cancer disease suffer from cardiac complications of anticancer treatment, it affects the quality of their lives and life expectancy, especially if the diagnosis is delayed. These patients may present distinct symptoms of cardiac injury, resulting from radiation-induced neurotoxicity and altered pain perception, which makes diagnosis difficult. This review highlights the need for a screening programme for patients who have undergone radiation therapy and which will subsequently have a potentially profound impact on morbidity and mortality.

Get Citation

Keywords

radiotherapy, ionizing radiation, radiation injuries, cardiotoxicity, neoplasms

About this article
Title

Cardiovascular complications after radiotherapy

Journal

Cardiology Journal

Issue

Ahead of print

Published online

2018-10-16

DOI

10.5603/CJ.a2018.0120

Pubmed

30338841

Keywords

radiotherapy
ionizing radiation
radiation injuries
cardiotoxicity
neoplasms

Authors

Izabela Nabiałek-Trojanowska
Ewa Lewicka
Anna Wrona
Anna M. Kaleta
Zuzanna Lewicka-Potocka
Grzegorz Raczak
Rafał Dziadziuszko

References (79)
  1. Gustavsson A, Osterman B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-Hodgkin’s lymphoma. Acta Oncol (Madr). 2003; 42(5-6): 605–619.
  2. Di Mattéo J, Vacheron A, Heulin A, et al. [Cardiac complications of thoracic radiotherapy]. Arch Mal Coeur Vaiss. 1978; 71(4): 447–452.
  3. Vacheron A, Heulin A, Baubion N, et al. Cardiac complications of radiotherapy. Ann Cardiol Angeiol (Paris) [Internet. 1983; 32(7): 465–472.
  4. Cuzick J, Stewart HJ, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Clinical Trials. 1987; 71(1): 7–14.
  5. Toltz A, Shin N, Mitrou E, et al. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential. J Appl Clin Med Phys. 2015; 16(5): 167–178.
  6. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109(5): 1878–1886.
  7. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(36): 2768–2801.
  8. Gaya AM, Ashford R. Cardiac complications of radiation therapy. Clin Oncol. 2005; 17(3): 153–159.
  9. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368(11): 987–998.
  10. Kremer L, Pal Hv, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002; 13(6): 819–829.
  11. Valagussa P, Zambetti M, Biasi S, et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994; 5(3): 209–216.
  12. Wrona A, Dziadziuszko R, Jassem J. Red.) Szymański F, Filipiak K, Warszawa IP 2017: 137-158. Radioterapia a ryzyko powikłań ze strony układu sercowo-naczyniowego. Nieklasyczne czynniki ryzyka chorób układu sercowo-naczyniowego w gabinecie lekarza praktyka [Internet]. ITEM Publishing; 2017. ITEM Publishing 2017: 137-158. Available from: http://bibliografia.gumed.edu.pl/cgi-bin/expertus.exe?KAT=f%3A%5Chidden%5Cexpertus%5Cparametr.02%5C&FST=data.fst&FDT=data.fdt&ekran=ISO&lnkmsk=2&cond=AND&mask=2&F_00=06&V_00=Nieklasyczne+czynniki+ryzyka+chor%F3b+uk%B3adu+sercowo-naczyniowego+w+gabinecie+l.
  13. Stewart J, Fajardo L, Gillette S, et al. Radiation injury to the heart. Int J Radiation Oncol *Biology* Physics. 1995; 31(5): 1205–1211.
  14. Rodemann H, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiotherapy Oncol. 1995; 35(2): 83–90.
  15. Hendry JH, Akahoshi M, Wang LiS, et al. Radiation-induced cardiovascular injury. Radiat Environ Biophys. 2008; 47(2): 189–193.
  16. Bhattacharya S, Asaithamby A. Ionizing radiation and heart risks. Semin Cell Dev Biol. 2016; 58: 14–25.
  17. Lancellotti P, Nkomo VT, Bergler-Klein J, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Hear J - Cardiovasc Imaging. 2013; 14(8): 721–740.
  18. Marlière S, Vautrin E, Saunier C, et al. Radiation-related heart toxicity: Update in women. Ann Cardiol Angeiol (Paris). 2016; 65(6): 411–419.
  19. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007; 25(25): 3991–4008.
  20. Kurowicki M, Zaucha R. Zastosowanie radioteraii w chłoniaku Hodgkina. Onkologia w praktyce klinicznej. 2014: 16–23.
  21. McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011; 100(2): 167–175.
  22. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003; 290(21): 2831–2837.
  23. Annest LS, Anderson RP, Li W, et al. Coronary artery disease following mediastinal radiation therapy. J Thorac Cardiovasc Surg. 1983; 85(2): 257–263.
  24. Orzan F, Brusca A, Conte MR, et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Heart. 1993; 69(6): 496–500.
  25. Gyenes G, Fornander T, Carlens P, et al. Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nuclear Med. 1997; 24(3): 286–292.
  26. Storey MR, Munden R, Strom EA, et al. Coronary artery dosimetry in intact left breast irradiation. Cancer J. 2001; 7(6): 492–497.
  27. Duane F, Aznar MC, Bartlett F, et al. A cardiac contouring atlas for radiotherapy. Radiother Oncol. 2017; 122(3): 416–422.
  28. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003; 42(4): 743–749.
  29. Amromin GD, Gildenhorn HL, Solomon RD, et al. The synergism of x-irradiation and cholesterol-fat feeding on the development of coronary artery lesions. J Atheroscl Res. 1964; 4(4): 325–334.
  30. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiotherapy Oncol. 1998; 46(1): 51–62.
  31. Hahn E, Jiang H, Ng A, et al. Late cardiac toxicity after mediastinal radiation therapy for hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys. 2017; 98(5): 1116–1123.
  32. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007; 116(17): 1971–1996.
  33. Iliescu C, Tsitlakidou D, Giza D, et al. Primary Percutaneous Coronary Interventions in Cancer Patients. Cancer Res Front. 2017; 3(1): 64–71.
  34. Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009; 95(3): 252–258.
  35. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014; 89(9): 1287–1306.
  36. Saxena P, Joyce LD, Daly RC, et al. Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience. Ann Thorac Surg. 2014; 98(6): 2115–2121.
  37. Donnellan E, Masri A, Johnston DR, et al. Long-Term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J Am Heart Assoc. 2017; 6(5): e005396.
  38. Fender EA, Chandrashekar P, Liang JJ, et al. Coronary artery bypass grafting in patients treated with thoracic radiation: a case-control study. Open Heart. 2018; 5(1): e000766.
  39. Zhuang XF, Yang YM, Sun XL, et al. Late onset radiation-induced constrictive pericarditis and cardiomyopathy after radiotherapy: A case report. Medicine (Baltimore). 2017; 96(5): e5932.
  40. Fajardo LF, Stewart JR. Experimental radiation-induced heart disease. Light microscopic studies. Am J Pathol. 1970; 59(2): 299–316.
  41. Vaitkus P, Herrmann HC, LeWinter MM. Treatment of Malignant Pericardial Effusion. JAMA: J Am Med Assoc. 1994; 272(1): 59.
  42. El Haddad D, Iliescu C, Yusuf SW, et al. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol. 2015; 66(10): 1119–1128.
  43. Nielsen KM, Offersen BV, Nielsen HM, et al. Short and long term radiation induced cardiovascular disease in patients with cancer. Clin Cardiol. 2017; 40(4): 255–261.
  44. Wang K, Pearlstein KA, Patchett ND, et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol. 2017; 125(2): 293–300.
  45. Orzan F, Brusca A. Radiation-induced constrictive pericarditis. Associated cardiac lesions, therapy and follow-up. G Ital Cardiol. 1994; 24(7): 817–823.
  46. Syed FF, Schaff HV, Oh JK. Constrictive pericarditis: a curable diastolic heart failure. Nat Rev Cardiol. 2014; 11(9): 530–544.
  47. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36(42): 2921–2964.
  48. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34(33): 2636–2648.
  49. Hering D, Faber L, Horstkotte D. Echocardiographic features of Radiation-Associated valvular disease. Am J Cardiol. 2003; 92(2): 226–230.
  50. Adams M, Hardenbergh P, Constine L, et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol. 2003; 45(1): 55–75.
  51. Madan R, Benson R, Sharma DN, et al. Radiation induced heart disease: Pathogenesis, management and review literature. J Egypt Natl Canc Inst. 2015; 27(4): 187–193.
  52. Tuohinen SS, Skyttä T, Poutanen T, et al. Radiotherapy-induced global and regional differences in early-stage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study. Int J Cardiovasc Imaging. 2017; 33(4): 463–472.
  53. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014; 100(21): 1673–1680.
  54. Umezawa R, Ota H, Takanami K, et al. MRI findings of radiation-induced myocardial damage in patients with oesophageal cancer. Clin Radiol. 2014; 69(12): 1273–1279.
  55. Skyttä T, Tuohinen S, Boman E, et al. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol. 2015; 10: 141.
  56. Opolski G, Krzakowski M, Szmit S, et al. Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer. The Task Force of National Consultants in Cardiology. Kardiol Pol. 2011; 69(5): 520–530.
  57. Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017; 35(8): 893–911.
  58. Tadic M, Cuspidi C, Hering D, et al. Radiotherapy-induced right ventricular remodelling: The missing piece of the puzzle. Arch Cardiovasc Dis. 2017; 110(2): 116–123.
  59. Groarke JD, Nguyen PL, Nohria A, et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014; 35(10): 612–623.
  60. Grover S, Leong DP, Chakrabarty A, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol. 2013; 168(6): 5465–5467.
  61. Tuohinen SS, Skyttä T, Virtanen V, et al. Detection of radiotherapy-induced myocardial changes by ultrasound tissue characterisation in patients with breast cancer. Int J Cardiovasc Imaging. 2016; 32(5): 767–776.
  62. Tadic M, Cuspidi C, Hering D, et al. The influence of chemotherapy on the right ventricle: did we forget something? Clin Cardiol. 2017; 40(7): 437–443.
  63. Vedovati MC, Giustozzi M, Verdecchia P, et al. Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study. Int J Cardiol. 2018; 269: 152–157.
  64. Laube ES, Yu A, Gupta D, et al. Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer. Am J Cardiol. 2017; 120(2): 213–217.
  65. Kalman PG, Lipton IH, Provan JL, et al. Radiation damage to large arteries. Can J Surg. 1983; 26(1): 88–91.
  66. Pherwani AD, Reid JA, Keane PF, et al. Synergism between radiotherapy and vascular risk factors in the accelerated development of atherosclerosis: a report of three cases. Ann Vasc Surg. 2002; 16(5): 671–675.
  67. Bergqvist D, Jonsson K, Nilsson M, et al. Treatment of arterial lesions after radiation therapy. Surg Gynecol Obstet. 1987; 165(2): 116–1120.
  68. Fajardo LF. Berthrong M. Vascular lesions following radiation. Pathol Ann. 1988; 23(1): 297–330.
  69. Timmers HULM, Wieling W, Karemaker JM, et al. Baroreflex failure: a neglected type of secondary hypertension. Neth J Med. 2004; 62(5): 151–155.
  70. Farach A, Fernando R, Bhattacharjee M, et al. Baroreflex failure following radiotherapy for head and neck cancer: A case study. Pract Radiat Oncol. 2012; 2(3): 226–232.
  71. Goldstein DS, Cheshire WP. Beat-to-beat blood pressure and heart rate responses to the Valsalva maneuver. Clin Auton Res. 2017; 27(6): 361–367.
  72. Goyal M, Shukla P, Gupta D, et al. Cardiovascular sequel of neck irradiation in head and neck cancer patients. Int J Radiat Biol. 2017; 93(7): 711–716.
  73. Huang CC, Huang TL, Hsu HC, et al. Long-term effects of neck irradiation on cardiovascular autonomic function: a study in nasopharyngeal carcinoma patients after radiotherapy. Muscle Nerve. 2013; 47(3): 344–350.
  74. Timmers HJ, Karemaker JM, Lenders JW, et al. Baroreflex failure following radiation therapy for nasopharyngeal carcinoma. Clin Auton Res. 1999; 9(6): 317–324.
  75. Goldstein DS. Neurocardiology: therapeutic implications for cardiovascular disease. Cardiovasc Ther. 2012; 30(2): e89–106.
  76. Krupicka J, Marková J, Pohlreich D, et al. Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin’s Lymphoma Study Group. Leuk Lymphoma. 2002; 43(12): 2325–2329.
  77. Andratschke N, Maurer J, Molls M, et al. Late radiation-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention. Radiother Oncol. 2011; 100(2): 160–166.
  78. Senkus-Konefka E, Jassem J. Cardiovascular effects of breast cancer radiotherapy. Cancer Treat Rev. 2007; 33(6): 578–593.
  79. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol. 2016; 142(2): 471–479.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl